Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/13/2005WO2005094839A1 Skin conditioning agent
10/13/2005WO2005094838A1 Drugs, foods and drinks for ameliorating hyperglycemia
10/13/2005WO2005094837A1 Use of a masticadienonic acid in the form of a dna polymerase beta inhibitor
10/13/2005WO2005094836A2 Use of loteprednol etabonate for the treatment of dry eye
10/13/2005WO2005094835A1 M3 muscarinic acetylcholine receptor antagonists
10/13/2005WO2005094834A1 Muscarinic acetylcholine receptor antagonists
10/13/2005WO2005094833A1 Novel n-substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators
10/13/2005WO2005094832A1 Compositions comprising meloxicam
10/13/2005WO2005094831A1 Sustained-release tablet formulation
10/13/2005WO2005094830A1 Combinations of signal transduction inhibitors
10/13/2005WO2005094829A1 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
10/13/2005WO2005094827A1 Methods for treating sexual dysfunction
10/13/2005WO2005094826A1 Anti-itching agent
10/13/2005WO2005094825A1 Controlled release pharmaceutical composition of tolperisone for oral administration
10/13/2005WO2005094824A1 Methods of enhancing cancer therapy by protecting nerve cells
10/13/2005WO2005094823A1 Flt-3 INHIBITOR
10/13/2005WO2005094821A1 A medical composition for increasing the medicine safety
10/13/2005WO2005094820A1 Treatment of impaired respiratory function with gaboxadol
10/13/2005WO2005094819A1 Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
10/13/2005WO2005094818A1 Azabicyclo-octane inhibitors of iap
10/13/2005WO2005094817A1 Melanin-concentrating hormone receptor antagonists and methods of use
10/13/2005WO2005094816A1 Indol-1-yl-acetic acid derivatives
10/13/2005WO2005094815A1 Dual inhibition of cyclooxygenase-2 and carbonic anhydrase
10/13/2005WO2005094814A1 External preparation
10/13/2005WO2005094813A1 Medicine for kidney disorder
10/13/2005WO2005094812A1 Nateglinide-containing preparation
10/13/2005WO2005094811A1 Pharmaceutical product containing tranilast
10/13/2005WO2005094810A2 Novel pharmaceutical compositions
10/13/2005WO2005094809A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
10/13/2005WO2005094808A1 Regulation of human glycine transporter 2
10/13/2005WO2005094807A1 Use of capsaicin and capsaicinoids for diagnosing chemical hypersensibility
10/13/2005WO2005094806A1 Use of quaternary ammonium compounds as specific blockers of transport through aquaporin, compositions comprising the compounds and method of selecting the compounds
10/13/2005WO2005094805A1 Imine derivative and amide derivative
10/13/2005WO2005094804A1 Gossypol co-crystals and the use thereof
10/13/2005WO2005094803A2 N3-pyridyl-thiamine and its use in cancer treatments
10/13/2005WO2005094802A2 Inhibiting proliferation of neoplastic cells by mlk inhibition
10/13/2005WO2005094801A1 Use of an nk3 antagonist for the treatment of bipolar disorders
10/13/2005WO2005094800A2 A co-precipitated cefepime composition and process for preparation thereof
10/13/2005WO2005094799A2 Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
10/13/2005WO2005094798A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
10/13/2005WO2005094797A2 Use of ampa-receptor antagonists for treating dementia
10/13/2005WO2005094796A2 Methods for interfering with fibrosis
10/13/2005WO2005094795A1 Use of beta2-sympathomimetics for balbuties treatment
10/13/2005WO2005094793A1 Process for preparing a solid pharmaceutical composition
10/13/2005WO2005094792A1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
10/13/2005WO2005094791A1 Preparation of lipid coated cefuroxime axetil
10/13/2005WO2005094789A1 S/o type pharmaceutical preparation and process for producing the same
10/13/2005WO2005094788A1 Fine dispersion of sparingly soluble drug and process for producing the same
10/13/2005WO2005094786A2 Coated tablet formulation and method
10/13/2005WO2005094785A2 Compositions capable of facilitating penetration across a biological barrier
10/13/2005WO2005094774A1 Skin lightening compositions comprising goya (momordica charantia) and pine extract
10/13/2005WO2005094724A1 Surgical adhesive formulations and methods of preparation
10/13/2005WO2005094579A1 Synergistic antimicrobial compositions and methods for reducing biofilm formation
10/13/2005WO2005094554A2 Therapeutic agents, methods, and treatments
10/13/2005WO2005094533A2 Trail-r as a negative regulator of innate immune cell responses
10/13/2005WO2005094457A2 Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof
10/13/2005WO2005094385A2 Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
10/13/2005WO2005094384A2 Methods and compositions for treatment of ion imbalances
10/13/2005WO2005094376A2 Synergistic methods and compositions for treating cancer
10/13/2005WO2005094374A2 Hydrazide-containing cftr inhibitor compounds and uses thereof
10/13/2005WO2005094373A2 Cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase and methods to reduce pulmonary infiltration by neutrophils
10/13/2005WO2005094358A2 Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs
10/13/2005WO2005094333A2 Multi-vitamin and mineral nutritional supplements
10/13/2005WO2005094329A2 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
10/13/2005WO2005094323A2 Process for preparing a dipeptidyl peptidase iv inhibitor and intermediates employed therein
10/13/2005WO2005094322A2 Effective treatment of tumors and cancer with triciribine and related compounds
10/13/2005WO2005094305A2 Combination therapy for weight management
10/13/2005WO2005094278A2 N-acylated chitinous polymers and methods of use thereof
10/13/2005WO2005094268A2 Treatment and prophylaxis of sepsis and septic shock
10/13/2005WO2005094234A2 Dietary supplement for treating digestive system disorders
10/13/2005WO2005094218A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
10/13/2005WO2005094210A2 Multi-action anthelmintic formulations
10/13/2005WO2005094203A2 Sodium ferric gluconate complexes and method of manufacture thereof
10/13/2005WO2005094202A2 Iron sucrose complexes and method of manufacture thereof
10/13/2005WO2005085268A3 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
10/13/2005WO2005084651A3 Methods for altering insulin secretion
10/13/2005WO2005082415A3 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
10/13/2005WO2005082375A3 Treatment of interstitial cystitis with vitamin d compounds
10/13/2005WO2005079766A3 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
10/13/2005WO2005079471A3 Cytotoxin compound and method of isolation
10/13/2005WO2005079170A3 Polypeptide participating in pyridoxine biosynthesis, a polynucleotide coding the polypeptide and those uses
10/13/2005WO2005077954A3 Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
10/13/2005WO2005076695A3 Methods of modulating neurotrophin-mediated activity
10/13/2005WO2005074945A3 Ketolide compounds for the treatment of atherosclerosis
10/13/2005WO2005074535A3 Cholinesterase inhibitors for spinal cord disorders
10/13/2005WO2005072505A3 Methods and compositions for the treatment of skin changes associated with aging and environmental damage
10/13/2005WO2005072113A3 Compositions and methods of treatment for inflammatory diseases
10/13/2005WO2005070910A3 Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
10/13/2005WO2005068468A3 Heterocyclic protein kinase inhibitors and uses thereof
10/13/2005WO2005068451A3 Methods for the synthesis of dictyostatin and derivatives and analogues thereof, stereochemical characterisation, novel dictyostatin compounds and uses thereof and synthetic intermediates
10/13/2005WO2005063260A3 Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
10/13/2005WO2005061458A3 Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
10/13/2005WO2005058352A3 Treatment of rheumatoid arthritis with galectin-3 antagonists
10/13/2005WO2005056525A3 Deacetylation of n-acetylglucosamine
10/13/2005WO2005053681A3 Novel uses of mevalonate pathway blockers
10/13/2005WO2005053658A8 Butylphthalide soft gel capsule and its preparatin procedure
10/13/2005WO2005051290A3 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone
10/13/2005WO2005046689A3 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
10/13/2005WO2005046634A3 Gastric juice-resistant form of administration
10/13/2005WO2005041867A3 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
1 ... 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 ... 7860